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ABSTRACT
Objective: To investigate the results and
complications of pectoralis major myocutaneous flap 
(PMMF) reconstruction in our department.
Methods: Twenty-three patients who underwent head 
and neck cancer resection and reconstruction with 
PMMF in our department between 1988 and February 
1998 were reviewed retrospectively. Results were 
assessed according to complications and risk factors.
Results: Flap-related complications developed in 9 
patients (39%); these were intraoperative vascular 
injury, total/partial flap necrosis, fistula formation and 
flap/suture line dehiscence. Blood albumin level was 
the most important risk factor for the development of 
complications. The median length of hospitalization for 
patients developing complications was 59 days 
compared with 18 days for those who did not develop 
complications.
Conclusion: Although variable new techniques for 
head and neck reconstruction are described, the 
PMMF still remains an excellent tool for single-stage 
reconstruction in the head and neck region. 
Unfortunately, the true complication rate after 
reconstruction with PMMF is not low. Many 
complications are undoubtedly related to risk factors 
and prolong hospitalization. These risk factors should 
be carefully considered and, if possible, treated 
preoperatively. Alternative reconstruction techniques 
should also be considered, and following general 
guidelines the best technique should be selected for 
each individual case.
K ey W ords: Flead and neck, Reconstruction, 
Pectoralis major myocutaneous flap, complications
INTRODUCTION
Although pectoralis major myocutaneous flap (PMMF) 
is first described by Hueston and McConchie in 1968 
(1), it is first used by Ariyan in 1979 (2,3). Since then, 
it remains the most common method used for 
reconstruction in head and neck surgery. The flap has 
proven to be versatile, reliable and easily applicable 
and sufficient experience has now been obtained 
about its limitations and complications (4). Overall 
complication rates of 35% to 68% have been reported 
with PMMF (5).
MATERIAL AND METHOD
In a 10-year period from 1988 to 1998 (February) 25 
PMMF reconstructions were performed on 23 
patients undergoing major head and neck surgery 
in our department. The case records were 
reviewed retrospectively and details of clinical 
information, operative procedure, immediate and 
delayed postoperative complications were retrieved. 
Tumour stages, laboratory profiles, associated 
conditions and hospitalization lengths, as well as 
the reasons for reconstruction, were all carefully 
reviewed. The causes and risk factors leading 
to complications were investigated but not 
analyzed statistically due to the limited number of 
patients.
* This article has been partly represented as oral presentation on the “24th National Congress of Otolaryngology and Head and 
Neck Surgery" held on between September, 23rd-27th 1997 in Antalya.
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RESULTS
PMMF reconstruction was performed on 20 (87%) 
male and 3 (13%) female patients. Their ages ranged 
from 22 to 80, with the majority in the 6th and 7th 
decades, the average age was 55,5. The sites of the 
primary tumours are shown in Table I.
Twenty-one of the 23 patients had squamous 
carcinoma of the upper aerodigestive tract, one patient 
had high-grade mucoepidermoid carcinoma and the 
other one had synovial sarcoma. Twenty-one patients 
were operated for primary tumours, the remaining two 
for recurrent disease. Tumour stages for the primary 
squamous carcinoma according to AJCC were as 
follows: 16 patients (76,2%) had Stage IV disease, 4 
patients (20%) Stage III and only 1 patient (4,8%) had 
Stage II disease. Two patients treated for recurrent 
disease had Stage III and Stage IV disease. Eight 
PMMFs (32%) were used to close mucosal opening in 
the oral cavity and oropharynx, 11 PMMFs (44%) for 
pharyngoesophageal reconstruction and 6 PMMFs 
(24%) to close skin defects or to preserve the carotid 
artery.
All complications occurring between the time of 
surgery and discharge from the hospital were listed 
regardless of their relative importance. Fourteen 
patients (61%) had a completely uneventful recovery. 
Nine patients (39%) developed flap complications 
which are listed in Table II.
Flap necrosis: Out of the 25 PMMFs, 6 (26%) were 
exposed to various degrees of flap necrosis. One
T a b le  I. Primary tumour sites
P rim a ry  tum our s ite s N o .o f ca se s (%)
Larynx 9 39,1
Hypopharynx 5 21,75
Auricula 2 8,7
Oral tongue 2 8,7
Tonsil 1 4,35
Parotis 1 4,35
Retromolar trigone 1 4,35
Alveolar ridge+Tongue base 1 4,35
Floor of the mouth 1 4,35
Total 23 100
patient had total flap necrosis, the other 5 partial flap 
necrosis. The patient developing total flap necrosis 
had most of the risk factors: was female and 
overweight, had Stage IV carcinoma of the oral tongue 
and an albumin level of less than 4 g/dl. Total flap 
necrosis and fistula formation were developed during 
radiotherapy in the first postoperative month. 
Conservative debridement was not effective and the 
biopsy taken from the fistula revealed a residual 
tumour. Therefore, the residual tongue was excised 
and reconstructed with the free forearm flap. 
Unfortunately, the residual tumour invaded the carotid 
artery, thus carotid ligation had to be done and the 
patient died on the 2nd postoperative day. In one 
patient the PMMF was injured intraoperatively and 
excised. Five patients developing partial flap 
necrosis were treated with conservative surgical 
debridement.
Fistula formation: Six patients (26%) developed 
fistulas. However, 3 of these fistulas (50%) closed 
spontaneously with conservative management. In 
three patients (50%), a second surgical procedure was 
necessary to close the fistula. Two of these patients 
underwent reconstruction with a PMMF from the 
contralateral side, one patient with an advancement 
flap.
Nine patients who developed complications were 
assessed regarding the various risk factors. The 
results are shown in Table III. As mentioned above, 
these results were not analyzed statistically due to the 
limited number of patients.
T a b le  II. Complications
C o m p lications No. of ca se s (%)
Total flap necrosis 1 4,35
Partial flap necrosis 5 21,75
Fistula development 6 26,1
Flap opening 1 4.35
Intraoperative vascular injury 1 4,35
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T a b le  II I . Comparison according to risk factors
Facto r C o m p lica tio n s (+) No co m p liactio n s Tota l
G ender
Male 7 13 20
Female 2 1 3
A verage age 
P rim ary  tum our s ite
60,7 52,2 55,5 (22-80)
Larynx 4 6 10
Tongue 1 1 2
Retromolar trigone 1 - 1
Floor of the mouth 1 - 1
Hypopharynx 2 2 4
Auricula - 2 2
Parotis - 1 1
Tongue base - 1 1
Tonsil - 1 1
P rim ary  tum our stage
Stage III - IV 9 13 22
Stage I - II 1 1
P atien t w eigth
Normal 3 7 10
Overweight 2 3 5
Underweight 4 4 8
Blood a lbum in  le ve l
<4 g/dl 6 4 10
4-5 g/dl 3 9 12
>5 g/dl - 1 1
P rev io us therapy
Tracheotomy 1 3 4
Radiotherapy - -
H o sp ita lizatio n  length 
(d a ys )
59,7 18 34,7 (12-91)
DISCUSSION
In the management of head and neck cancer, 
reconstruction is an absolute necessity rather than an 
option. The chosen method for reconstruction must be 
consistent with the hierarchy of treatment priorities: 
survival, followed by function, freedom from pain and 
cosmetic (6).
Since its introduction in 1979 by Ariyan (2,3), the 
PMMF has become the most commonly used pedicled 
muscle flap for head and neck reconstruction. It
provides a great amount of tissue, has a reliable 
vascular supply, is easy to harvest and appropriate for 
single-stage reconstruction (7). But it also has 
limitations and complications and one should bear in 
mind that it is not ideal for every head and neck defect. 
The disadvantages of the PMMF are its bulkiness, 
wound problems, swallowing dysfunction, deformity on 
the chest wall and hair growth interfering with hygiene
(5,7). Moreover, serious complications can develop. 
Overall complication rates of 35% to 68% have been 
reported (5). This difference depends on the number of 
cases in these reports and on the experience of each
84
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T Ü M  B Ö L G E L E R D E
Kalça kırığı oluşma insidansını % 51  
oranında ve diğer kritik osteoporoz 
bölgelerinde kırık insidansını önemli 
derecede azaltmıştır (p=0,047).1
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department and moreover on the definition of 
complication. The definition of complication differs in 
the literature (4). Some authors reported a low rate of 
complications, but significance and complication have 
obviously been interpreted differently in most 
instances and the definition of complication is not clear
(4). Furthermore, the underlying causes and the 
impact of complications are seldom reported (4). 
Mehrhoff et al (8 ) reported a complication rate of 6 8 % 
in 73 flaps, similarly Kroll et al (9) reported 63% 
complications in 168 flaps. In their review of 211 
patients in 1990, Shah et al found a complication rate 
of 63% (4). Our complication rate of 39% is consistent 
with the literature. Although these rates seem to be 
very high, many of the complications are easily treated 
with conservative management. The incidence of 
partial or total flap necrosis ranges from 2 to 33% in 
the literature (5). Shindo et al reported a total flap 
necrosis rate of 4% and a partial flap necrosis rate of
5-17% (7). These rates are 4,5% and 22% in our 
patients. The fistula rate in our cases is 26%, similarly 
to that of 29% reported by Shah et al (4). One of 6 
patients (17%) developing flap necrosis and 3 of 6 
patients (50%) developing fistula required a second 
surgical intervention, these rates are higher than in the 
literature. We observed no donor site complication 
which is reported as being up to 19% in the literature
(10).
In their review of 211 cases in 1990 (4), Shah et al 
described some risk factors: age greater than 70 
years, female sex, primary tumour in the oral cavity, 
tumour stage III or IV, overweight and a blood albumin 
level less than 4 g/dl. Table V shows the comparison 
of our cases according to these risk factors. Seven of 
20 male patients (35%) and 2 of 3 female patients 
(67%) developed complications, but the number of our 
cases is not enough to accept the female sex as a risk 
factor. No correlation between body weight and 
complication rate could be found. Blood albumin level 
was the most important risk factor for developing 
complications. Resection for Stage III or IV tumours of 
the oral cavity or laryngopharynx is undoubtedly a risk 
factor for PMMF complications. These findings are 
similar to those of Shah et al, with the exception of sex 
and body weight. The only patient developing total flap 
necrosis is female, overweight, and also has low 
albumin level and Stage IV tongue carcinoma. None of 
our patients had received radiotherapy prior to 
surgery, therefore we were not able to evaluate the 
impact of radiotherapy on flap survival. Some authors 
suggest that radiotherapy prior to surgery increases 
the risk of fistula formation and, if a fistula occurres,
prolongs the closure time with conservative 
management (11 ), whereas some authors propose 
that it has either no effect or only a minimal effect on 
major or minor morbidity (4,11). Complications in our 
patients resulted in prolongation of their hospital stay, 
as also reported by Shah et al (4).
In conclusion, PMMF still remains an excellent tool for 
routine immediate reconstruction in head and neck 
surgery despite a variety of new techniques described. 
Unfortunately, the true complication rate following 
PMMF reconstruction is not low and undoubtedly 
related to risk factors. Thus, its limitations should be 
carefully considered and if possible, risk factors should 
be eliminated before surgery.
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